BioSpace News Archive

Baylor Genetics announced the availability of an Epilepsy Panel and a STAT Epilepsy Panel - with the latter intended for patients with new onset or change in seizure frequency or character.

AscellaHealth LLC announces its commitment to provide NeuroSolv Therapeutics LLC with AscellaHealth’s comprehensive suite of services to support NeuroSolv’s clinical development and commercialization of Perineline™, a two-part, non-surgical therapy aimed at improving the treatment options available for patients with spinal cord injury.

L7 Informatics, Inc, the leading provider of scientific solutions for research, development, manufacturing, and quality control, is delighted to announce the expansion of its European operations

CHA Hollywood Presbyterian Medical Center is proud to announce its participation in a prestigious $40.5 million, multisite study funded by a grant from the National Institute on Aging, part of the National Institutes of Health, for the development of the Asian Cohort for Alzheimer’s Disease.

ZEISS is unveiling two highlights at M&M 2023, in Minneapolis, MN, from July 23 to July 27, 2023.

Alveo Technologies, Inc., a leader in molecular sensing and diagnostics with its proprietary be.well™ technology platform, launched a web-based partner portal and suite of enablement software tools to further drive innovative partnerships onto the platform to co-develop and commercialize rapid, point of need diagnostic solutions across multiple life sciences industry sectors.

Urotronic, Inc. today announced it has received U.S. Food and Drug Administration (FDA) approval of its Optilume® BPH Catheter System, a unique minimally invasive surgical therapy (MIST) that combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel for the treatment of lower urinary tract symptoms (LUTS) secondary to BPH.

In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia areata.

SYNAPS Dx (SDx) a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), recognizes the historic Food and Drug Administration (FDA) approval of Leqembi, the first drug shown to slow the progression of AD.

EverythingALS and CureALS, two prominent organizations dedicated to finding a cure for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, are thrilled to announce their merger and unified operations on the EverythingALS platform.